Recognizing Carcinoid Heart Disease and Timing of Cardiac and Abdominal Procedures Abstract #261

Introduction: Recognition of right heart failure in Carcinoid Heart Disease enables a decision to be made concerning the proper timing of Cardiac and abdominal tumor-reductive surgery.
Aim(s): Review of 11 patients operated for carcinoid heart disease to relieve hepatic congestion, enabling subsequent abdominal tumor-reductive procedures.
Materials and methods: From 2000 through 2010, 11 patients with severe right heart failure underwent right heart valve replacement because they were deemed at extreme risk for tumor-reductive abdominal procedures. A retrospective review focused upon the influence of right heart failure on the risk of tumor-reductive abdominal procedures and the sequencing of procedures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Dr. Jerome S Zacks

To read results and conclusion, please login ...

Further abstracts you may be interested in

#137 Extensive ""multitasking"" surgery for advanced neuroendocrine tumors is safe and effective
Introduction: Management of advanced NETs is controversial, related to degree of intervention; the pendulum is swinging towards a more aggressive interventional approach. Our Center's philosophy is to offer a systematic, planned multimodality treatment for patients with advanced NETs.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD MICHAIL K Shafir
#461 The Good, the Bad, the Unexpected
Introduction: GEP NETs constitute less than 2% of all gastrointestinal malignancies; usually they are age-related with the highest incidence above the fifth decade. Primary GEP NETs are often asymptomatic, sometimes being incidentally discovered in resected surgical specimens when surgery has been undertaken for other intra-abdominal disease.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Sorina Martin
Authors: Martin S, Micu A, Fica S, ...
#1041 Surgical Management of Carcinoid Valve Disease-Mechanical versus Tissue Valves
Introduction: The prosthetic valve of choice in patients with carcinoid valve disease (CVD) remains controversial due to the limited life expectancy of patients with advanced-stage neuroendocrine tumors (NETs) on one hand, and concerns regarding structural valve deterioration (SVD) on the other.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Surgical treatment
Presenting Author: MD Simona Glasberg
Authors: Glasberg S, Atlan J, Korach A, Dabah A, ...
#1138 Staged Percutaneous Treatment of Severe Carcinoid Heart Disease by Transfemoral Pulmonary Valve Replacement and Novel Vena Cava Valve Implantation
Introduction: Carcinoid heart disease with severe valve destruction represents the major cause of high morbidity and mortality in patients with carcinoid syndrome.
Conference: 12th Annual ENETS Conference 2015 (2015)
Category: Clinical cases/reports
Presenting Author: Dr René Pschowski
Authors: Pschowski R, Laule M, Baur A, Pape U F, ...
#1272 Telotristat Etiprate Appears to Halt Carcinoid Heart Disease
Introduction: Carcinoid Heart Disease (CHD) is a serious complication of the Carcinoid Syndrome (in as many as 50% of patients during the course of their disease). 46% of cases operated with bioprosthetic valves develop recurrent carcinoid valvulopathy on the newly implanted tissue valves. Until now, only mechanical prosthetic valves avoid recurrent fibrosis.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Others
Presenting Author: MD, FACC, FCCP Jerome Zacks
Authors: Zacks J, Lavine R, Ratner L, Warner R, ...